NDC 73063-035
RELYVRIO
Sodium Phenylbutyrate/taurursodiol
RELYVRIO is a Oral Powder, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Amylyx Pharmaceuticals Inc. The primary component is Sodium Phenylbutyrate; Taurursodiol.
| Product ID | 73063-035_a9d047a0-e5f6-441b-89d5-994766d6afcb |
| NDC | 73063-035 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RELYVRIO |
| Generic Name | Sodium Phenylbutyrate/taurursodiol |
| Dosage Form | Powder, For Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2022-09-29 |
| Marketing Category | NDA / |
| Application Number | NDA216660 |
| Labeler Name | Amylyx Pharmaceuticals Inc |
| Substance Name | SODIUM PHENYLBUTYRATE; TAURURSODIOL |
| Active Ingredient Strength | 3 g/1; g/1 |
| Pharm Classes | Ammonium Ion Binding Activity [MoA], Nitrogen Binding Agent [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 73063-035-03
56 POWDER, FOR SUSPENSION in 1 CARTON (73063-035-03)
| Marketing Start Date | 2022-09-29 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [RELYVRIO]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 RELYVRIO 90544439 not registered Live/Pending |
Amylyx Pharmaceuticals, Inc. 2021-02-24 |
© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.